Tissue-based Biomarkers Steering Clinical Decisions in Patients with Urothelial Cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 39266382.
- Also identified by DOI 10.1016/j.eururo.2024.08.033.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The European Association of Urology (EAU), National Comprehensive Cancer Network, and European Society for Medical Oncology guidelines recommend PD-L1 and FGFR testing for patients with locally advanced bladder cancer or upper tract urothelial cancer (UTUC) according to specific eligibility criteria; positive results indicate therapy with immune checkpoint inhibitors or erdafitinib, respectively. The EAU guidelines recommend PD-L1 testing for subsequent adjuvant therapy in high-risk UC, and germline DNA sequencing in patients with UTUC positive for DNA mismatch repair alterations.
Medical subject headings
- Carcinoma, Transitional Cell
- Biomarkers, Tumor
- Clinical Decision-Making